These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 9399017)

  • 21. The novel anti-migraine compound zolmitriptan (Zomig 311C90) has no clinically significant interactions with paracetamol or metoclopramide.
    Seaber EJ; Ridout G; Layton G; Posner J; Peck RW
    Eur J Clin Pharmacol; 1997; 53(3-4):229-34. PubMed ID: 9476036
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Emerging preclinical and clinical profile of 311C90: a poster review and discussion.
    Ferrari MD
    Eur Neurol; 1996; 36 Suppl 2():19-23. PubMed ID: 8791028
    [No Abstract]   [Full Text] [Related]  

  • 23. 311C90: patient profiles and typical case histories of migraine management.
    Dowson AJ
    Neurology; 1997 Mar; 48(3 Suppl 3):S29-33. PubMed ID: 9071268
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of nonresponders to oral sumatriptan with zolmitriptan and rizatriptan: a comparative open trial.
    Mathew NT; Kailasam J; Gentry P; Chernyshev O
    Headache; 2000 Jun; 40(6):464-5. PubMed ID: 10849042
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical safety of 311C90: aggregated data from patients and volunteers to date.
    Earl NL
    Eur Neurol; 1996; 36 Suppl 2():8-12. PubMed ID: 8791026
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Can oral 311C90, a novel 5-HT1D agonist, prevent migraine headache when taken during an aura?
    Dowson A
    Eur Neurol; 1996; 36 Suppl 2():28-31. PubMed ID: 8791030
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comparative trial of zolmitriptan and sumatriptan for the acute oral treatment of migraine.
    Gallagher RM; Dennish G; Spierings EL; Chitra R
    Headache; 2000 Feb; 40(2):119-28. PubMed ID: 10759911
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the efficacy of zolmitriptan and sumatriptan: issues in migraine trial design.
    Geraud G; Olesen J; Pfaffenrath V; Tfelt-Hansen P; Zupping R; Diener HC; Sweet R
    Cephalalgia; 2000 Feb; 20(1):30-8. PubMed ID: 10817444
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intensity dependence of the cortical auditory evoked potentials as a surrogate marker of central nervous system serotonin transmission in man: demonstration of a central effect for the 5HT1B/1D agonist zolmitriptan (311C90, Zomig).
    Proietti-Cecchini A; Afra J; Schoenen J
    Cephalalgia; 1997 Dec; 17(8):849-54; discussion 799. PubMed ID: 9453273
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Zolmitriptan].
    Le Jeunne C
    Presse Med; 1999 Sep; 28(28):1525-6. PubMed ID: 10526561
    [No Abstract]   [Full Text] [Related]  

  • 31. Peripheral vascular effects and pharmacokinetics of the antimigraine compound, zolmitriptan, in combination with oral ergotamine in healthy volunteers.
    Dixon RM; Meire HB; Evans DH; Watt H; On N; Posner J; Rolan PE
    Cephalalgia; 1997 Oct; 17(6):639-46. PubMed ID: 9350383
    [TBL] [Abstract][Full Text] [Related]  

  • 32. No need to adjust the dose of 311C90 (zolmitriptan), a novel anti-migraine treatment, in patients with renal failure not requiring dialysis.
    Gillotin C; Bagnis C; Mamet JP; Peck RW; Deray G
    Int J Clin Pharmacol Ther; 1997 Nov; 35(11):522-6. PubMed ID: 9401835
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Zolmitriptan provides consistent migraine relief when used in the long-term.
    Tuchman M; Edvinsson L; Geraud G; Korczyn A; Mauskop A; Pfaffenrath V
    Curr Med Res Opin; 1999; 15(4):272-81. PubMed ID: 10640259
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90).
    Seaber E; On N; Dixon RM; Gibbens M; Leavens WJ; Liptrot J; Chittick G; Posner J; Rolan PE; Pack RW
    Br J Clin Pharmacol; 1997 Jun; 43(6):579-87. PubMed ID: 9205817
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Zolmitriptan receives migraine indication.
    Am J Health Syst Pharm; 1998 Jan; 55(2):110, 113. PubMed ID: 9465973
    [No Abstract]   [Full Text] [Related]  

  • 36. Zolmitriptan versus a combination of acetylsalicylic acid and metoclopramide in the acute oral treatment of migraine: a double-blind, randomised, three-attack study.
    Geraud G; Compagnon A; Rossi A;
    Eur Neurol; 2002; 47(2):88-98. PubMed ID: 11844897
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Zolmitriptan].
    Monseu G; Sternon J
    Rev Med Brux; 1998 Dec; 19(6):495-9. PubMed ID: 9916496
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Zolmitriptan for migraine.
    Med Lett Drugs Ther; 1998 Feb; 40(1021):27-8. PubMed ID: 9505961
    [No Abstract]   [Full Text] [Related]  

  • 39. Receptor specificity and trigemino-vascular inhibitory actions of a novel 5-HT1B/1D receptor partial agonist, 311C90 (zolmitriptan).
    Martin GR; Robertson AD; MacLennan SJ; Prentice DJ; Barrett VJ; Buckingham J; Honey AC; Giles H; Moncada S
    Br J Pharmacol; 1997 May; 121(2):157-64. PubMed ID: 9154322
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of rizatriptan 10 mg vs. zolmitriptan 2.5 mg in the acute treatment of migraine. Rizatriptan-Zolmitriptan Study Group.
    Pascual J; Vega P; Diener HC; Allen C; Vrijens F; Patel K
    Cephalalgia; 2000 Jun; 20(5):455-61. PubMed ID: 11037741
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.